Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.76)
# 567
Out of 4,810 analysts
59
Total ratings
48.78%
Success rate
8.26%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $15.14 | +25.50% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $323.44 | +20.58% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $42.93 | +28.12% | 3 | Feb 25, 2025 | |
| RGEN Repligen | Maintains: Overweight | $190 → $200 | $126.62 | +57.95% | 5 | Feb 21, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $44.85 | +22.63% | 1 | Feb 21, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $12 | $8.16 | +47.06% | 3 | Feb 13, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $35 → $40 | $39.50 | +1.27% | 1 | Feb 4, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $103.12 | +55.16% | 6 | Nov 26, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $650 → $670 | $441.00 | +51.93% | 8 | Sep 20, 2024 | |
| HSIC Henry Schein | Maintains: Overweight | $88 → $80 | $64.28 | +24.46% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $8.01 | +149.69% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.19 | - | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,046.58 | +33.77% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $7.74 | -22.48% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $95.54 | +25.60% | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.27 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $38.43 | +134.19% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $189.92 | +42.17% | 4 | Dec 20, 2023 |
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $15.14
Upside: +25.50%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $323.44
Upside: +20.58%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $42.93
Upside: +28.12%
Repligen
Feb 21, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $126.62
Upside: +57.95%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $44.85
Upside: +22.63%
10x Genomics
Feb 13, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.16
Upside: +47.06%
Twist Bioscience
Feb 4, 2025
Maintains: Underweight
Price Target: $35 → $40
Current: $39.50
Upside: +1.27%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $103.12
Upside: +55.16%
Thermo Fisher Scientific
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $441.00
Upside: +51.93%
Henry Schein
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $64.28
Upside: +24.46%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $8.01
Upside: +149.69%
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,046.58
Upside: +33.77%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $7.74
Upside: -22.48%
Jul 30, 2024
Maintains: Neutral
Price Target: $105 → $120
Current: $95.54
Upside: +25.60%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $38.43
Upside: +134.19%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $189.92
Upside: +42.17%